Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 50

1.

Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer: interim efficacy results of the randomised, open-label, non-inferiority, phase 3 TURANDOT trial.

Lang I, Brodowicz T, Ryvo L, Kahan Z, Greil R, Beslija S, Stemmer SM, Kaufman B, Zvirbule Z, Steger GG, Melichar B, Pienkowski T, Sirbu D, Messinger D, Zielinski C; Central European Cooperative Oncology Group..

Lancet Oncol. 2013 Feb;14(2):125-33. doi: 10.1016/S1470-2045(12)70566-1. Epub 2013 Jan 10.

PMID:
23312888
2.

Adjuvant docetaxel, doxorubicin, and cyclophosphamide in node-positive breast cancer: 10-year follow-up of the phase 3 randomised BCIRG 001 trial.

Mackey JR, Martin M, Pienkowski T, Rolski J, Guastalla JP, Sami A, Glaspy J, Juhos E, Wardley A, Fornander T, Hainsworth J, Coleman R, Modiano MR, Vinholes J, Pinter T, Rodríguez-Lescure A, Colwell B, Whitlock P, Provencher L, Laing K, Walde D, Price C, Hugh JC, Childs BH, Bassi K, Lindsay MA, Wilson V, Rupin M, Houé V, Vogel C; TRIO/BCIRG 001 investigators..

Lancet Oncol. 2013 Jan;14(1):72-80. doi: 10.1016/S1470-2045(12)70525-9. Epub 2012 Dec 12.

PMID:
23246022
3.

Carpal tunnel syndrome and musculoskeletal symptoms in postmenopausal women with early breast cancer treated with exemestane or tamoxifen after 2-3 years of tamoxifen: a retrospective analysis of the Intergroup Exemestane Study.

Mieog JS, Morden JP, Bliss JM, Coombes RC, van de Velde CJ; IES Steering Committee..

Lancet Oncol. 2012 Apr;13(4):420-32. doi: 10.1016/S1470-2045(11)70328-X. Epub 2012 Jan 20.

PMID:
22265698
4.

Adjuvant trastuzumab in HER2-positive breast cancer.

Slamon D, Eiermann W, Robert N, Pienkowski T, Martin M, Press M, Mackey J, Glaspy J, Chan A, Pawlicki M, Pinter T, Valero V, Liu MC, Sauter G, von Minckwitz G, Visco F, Bee V, Buyse M, Bendahmane B, Tabah-Fisch I, Lindsay MA, Riva A, Crown J; Breast Cancer International Research Group..

N Engl J Med. 2011 Oct 6;365(14):1273-83. doi: 10.1056/NEJMoa0910383.

5.

Combination therapy of lapatinib and Capecitabine for ErbB2-positive metastatic or locally advanced breast cancer: results from the Lapatinib Expanded Access Program (LEAP) in Central and Eastern Europe.

Greil R, Borštnar S, Petráková K, Marcou Y, Pikiel J, Wojtukiewicz MZ, Koza I, Steger GG, Linn M, Das Gupta A, Cwiertka K.

Onkologie. 2011;34(5):233-8. doi: 10.1159/000327710. Epub 2011 Apr 26.

6.

First-line bevacizumab plus taxane-based chemotherapy for locally recurrent or metastatic breast cancer: safety and efficacy in an open-label study in 2,251 patients.

Smith IE, Pierga JY, Biganzoli L, Cortés-Funes H, Thomssen C, Pivot X, Fabi A, Xu B, Stroyakovskiy D, Franke FA, Kaufman B, Mainwaring P, Pienkowski T, De Valk B, Kwong A, González-Trujillo JL, Koza I, Petrakova K, Pereira D, Pritchard KI; ATHENA Study Group..

Ann Oncol. 2011 Mar;22(3):595-602. doi: 10.1093/annonc/mdq430. Epub 2010 Sep 5.

PMID:
20819780
7.

Cetuximab plus FOLFOX6 or FOLFIRI in metastatic colorectal cancer: CECOG trial.

Ocvirk J, Brodowicz T, Wrba F, Ciuleanu TE, Kurteva G, Beslija S, Koza I, Pápai Z, Messinger D, Yilmaz U, Faluhelyi Z, Yalcin S, Papamichael D, Wenczl M, Mrsic-Krmpotic Z, Shacham-Shmueli E, Vrbanec D, Esser R, Scheithauer W, Zielinski CC.

World J Gastroenterol. 2010 Jul 7;16(25):3133-43.

8.

Gemcitabine and carboplatin treatment in patients with relapsing ovarian cancer.

Sufliarsky J, Chovanec J, Svetlovska D, Minarik T, Packan T, Kroslakova D, Lalabova R, Helpianska L, Horvathova D, Sevcik L, Spacek J, Laluha A, Tkacova V, Malec V, Rakicka G, Magdin D, Jancokova I, Dorr A, Stresko M, Habetinek V, Koza I.

Neoplasma. 2009;56(4):291-7.

PMID:
19473054
9.

Paclitaxel, bleomycin, etoposide, and cisplatin (T-BEP) as initial treatment in patients with poor-prognosis germ cell tumors (GCT): a phase II study.

Mardiak J, Sálek T, Sycová-Milá Z, Obertová J, Recková M, Mego M, Hlavatá Z, Brozmanová K, Risnyovzská Z, Svetlovská D, Koza I.

Neoplasma. 2007;54(3):240-5.

PMID:
17447857
10.

Paclitaxel plus ifosfamide and cisplatin in second-line treatment of germ cell tumors: a phase II study.

Mardiak J, Sálek T, Sycová-Milá Z, Obertová J, Hlavatá Z, Mego M, Recková M, Koza I.

Neoplasma. 2005;52(6):497-501.

PMID:
16284696
11.

Prevention of febrile neutropenia in cancer patients by probiotic strain Enterococcus faecium M-74. Phase II study.

Mego M, Koncekova R, Mikuskova E, Drgona L, Ebringer L, Demitrovicova L, Nemova I, Trupl J, Mardiak J, Koza I, Zajac V.

Support Care Cancer. 2006 Mar;14(3):285-90. Epub 2005 Sep 21.

PMID:
16175356
12.

Gemcitabine plus cisplatine and paclitaxel (GCP) in second-line treatment of germ cell tumors (GCT): a phase II study.

Mardiak J, Sálek T, Sycová-Milá Z, Obertová J, Hlavatá Z, Mego M, Recková M, Koza I.

Neoplasma. 2005;52(3):243-7.

PMID:
15875087
13.

Prevention of febrile neutropenia in cancer patients by probiotic strain Enterococcus faecium M-74. Pilot study phase I.

Mego M, Ebringer L, Drgona L, Mardiak J, Trupl J, Greksak R, Nemova I, Oravcova E, Zajac V, Koza I.

Neoplasma. 2005;52(2):159-64.

PMID:
15800715
14.

[Perspectives of medical therapy of solid tumours].

Koza I.

Vnitr Lek. 2001 Aug;47(8):510-5. Review. Slovak.

PMID:
15633386
16.

Carboplatin and cyclophosphamide in the treatment of metastatic seminoma.

Mardiak J, Sálek T, Sycova-Milá Z, Sufliarsky J, Baláz M, Koza I.

Neoplasma. 2000;47(4):244-7.

PMID:
11043830
17.

Sequential intermediate high-dose therapy with etoposide, ifosfamide and cisplatin for patients with germ cell tumors.

Mardiak J, Fuchsberger P, Lakota J, Sálek T, Sycová-Milá Z, Drahokoupilová M, Baláz M, Koza I.

Neoplasma. 2000;47(4):239-43.

PMID:
11043829
18.

[Effectiveness of cisplatin with continuous infusion of 5-fluorouracil in neoadjuvant chemotherapy of carcinoma of the oral cavity].

Poruban D, Koza I, Mracna J, Nagy V, Vasko J.

Bratisl Lek Listy. 1992 Aug;93(8):395-400. Slovak.

PMID:
1464019
19.

Candidosis, aspergillosis and zygomycosis in an oncology department.

Krcméry V Jr, Koza I, Fuchsberger P, Spánik S, Trupl J, Gyarfás J, Sufliarsky J, Agh F, Horváth A, Mardiak J, et al.

Mycoses. 1992 Jul-Aug;35(7-8):189-91.

PMID:
1287485
20.

Netilmicin plus ceftriaxone versus amikacin plus ceftriaxone in the treatment of infections in granulocytopenic patients.

Krcméry V Jr, Koza I, Mardiak J, Fuchsberger P, Spánik S, Trupl J, Horníková M, Kusenda Z, Sufliarsky J, Svec J.

Chemotherapy. 1992;38(1):74-6.

PMID:
1618007

Supplemental Content

Loading ...
Support Center